유럽 ​​방광 장애 시장 – 2029년까지의 산업 동향 및 예측

TOC 요청 TOC 요청 분석가에게 문의 분석가에게 문의 지금 구매 지금 구매 구매하기 전에 문의 구매하기 전에 문의 무료 샘플 보고서 무료 샘플 보고서

유럽 ​​방광 장애 시장 – 2029년까지의 산업 동향 및 예측

  • Pharmaceutical
  • Published Report
  • Sep 2022
  • Europe
  • 350 Pages
  • 테이블 수: 89
  • 그림 수: 35

Europe Bladder Disorders Market

시장 규모 (USD 10억)

연평균 성장률 :  % Diagram

Diagram 예측 기간
2022 –2029
Diagram 시장 규모(기준 연도)
USD 2,332.69 Million
Diagram 시장 규모(예측 연도)
USD 5,226.00 Million
Diagram 연평균 성장률
%
Diagram주요 시장 플레이어
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>유럽 ​​방광 장애 시장, 유형별(방광염, 요실금, 과민성 방광, 간질성 방광염 , 방광암), 치료 유형(수술, 약물, 비수술), 최종 사용자(병원, 진료소, 외래 수술 센터, 기타), 유통 채널(직접, 소매) - 업계 동향 및 2029년까지의 전망.

유럽 ​​방광 장애 시장

유럽 ​​방광 장애 시장 분석 및 통찰력 

방광 장애는 인간의 일상 생활에 영향을 미칠 수 있는 장애군입니다. 가장 흔한 방광 장애 중 일부는 방광이 감염되어 염증을 일으키는 방광염입니다. 요실금 - 방광 조절 상실, 간질성 방광염 - 방광 통증과 빈번하고 긴박한 배뇨, 과민성 방광 - 방광이 소변을 짜내는 상태입니다. 방광 장애는 삶의 질에 영향을 미치고 다른 건강 문제를 일으킬 수 있습니다. 신경계 및 생활 방식 요인을 포함한 건강 변화와 문제는 남성과 여성의 UI를 일으키거나 이에 기여할 수 있습니다.

유럽 ​​방광 장애 시장

유럽 ​​방광 장애 시장

가장 흔한 방광 장애는 과민성 방광과 UI입니다. 이러한 문제는 신경계와 관련이 있습니다. 신경은 뇌에서 방광으로 메시지를 전달하여 근육이 수축하거나 이완되도록 합니다.

유럽 ​​방광 장애 시장은 2022년부터 2029년까지의 예측 기간 동안 성장할 것으로 예상됩니다. Data Bridge Market Research는 시장이 2022년부터 2029년까지의 예측 기간 동안 10.7%의 CAGR로 성장하고 있으며 2021년 2,332.69백만 달러에서 2029년까지 5,226.00백만 달러에 도달할 것으로 분석합니다.

보고서 메트릭

세부

예측 기간

2022년부터 2029년까지

기준 연도

2021

역사적 연도

2020 (2019-2014 사용자 정의 가능)

양적 단위

수익 (단위: USD 백만)

다루는 세그먼트

유형별(방광염, 요실금, 과민성 방광, 간질성 방광염, 방광암), 치료 유형별(수술, 약물, 비수술), 최종 사용자별(병원, 진료소, 외래 수술 센터, 기타), 유통 채널별(직접, 소매)

적용 국가

독일, 프랑스, ​​영국, 이탈리아, 스페인, 네덜란드, 러시아, 스위스, 터키, 오스트리아, 노르웨이, 헝가리, 리투아니아, 아일랜드, 폴란드, 유럽의 나머지 지역

시장 참여자 포함

이 시장에 참여하고 있는 주요 기업으로는 Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (KYORIN Holdings, Inc.의 자회사), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Urovant Sciences 등이 있습니다.

유럽 ​​방광 장애 시장의 시장 정의

Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, urinary incontinence - loss of bladder control, overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.

Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.

Anticholinergic medications are the first-line of pharmacotherapy in overactive bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.

Europe Bladder Disorders Market Dynamics

Drivers

  • STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.

  • GROWING GERIATRIC POPULATION

Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can dispose to the development of OAB and Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

  • RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

  • COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

  • SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.

  • RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems coupled with increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This Bladder Disorders Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Europe Bladder Disorders Market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Europe Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

  • 2월에 AbbVie는 5세 소아 환자의 신경학적 상태와 관련된 방광근 과활성을 치료하기 위한 BOTOX®에 대한 미국 FDA 승인을 발표했습니다. "BOTOX®는 항콜린제 요법으로 성공적으로 치료할 수 없는 상태를 가진 어린이의 신경성 방광근 과활성을 치료하기 위해 승인된 최초의 신경 독소입니다." 이 승인은 회사의 수익을 증가시킬 것입니다.

유럽 ​​방광 장애 시장 범위

유럽 ​​방광 장애 시장은 유형, 치료 유형, 최종 사용자 및 유통 채널로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내릴 수 있는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.

유형

  • 방광염
  • 요실금
  • 과민성 방광
  • 간질성 방광염
  • 방광암

유럽 ​​방광 장애 시장은 유형에 따라 방광염, 요실금, 과민성 방광, 간질성 방광염 및 방광암으로 구분됩니다.

치료 유형

  • 수술
  • 약물
  • 기타

제품을 기준으로 유럽 방광 장애 시장은 수술, 약물 및 기타로 세분화됩니다.

최종 사용자

  • 병원
  • 클리닉
  • 외래 수술 센터
  • 기타

최종 사용자를 기준으로 유럽 방광 장애 시장은 병원, 진료소, 외래 수술 센터 및 기타로 세분화됩니다.

유통 채널

  • 직접
  • 소매

방광 장애 시장

유통 채널을 기준으로 유럽 방광 장애 시장은 직접 및 소매로 세분화됩니다.

유럽 ​​방광 장애 시장 지역 분석/통찰력  

위에 언급된 대로, 유럽 방광 장애 시장을 분석하고, 국가, 유형, 치료 유형, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.

이 시장에 포함된 국가는 독일, 영국, 프랑스, ​​이탈리아, 스페인, 터키, 러시아, 네덜란드, 스위스, 벨기에 및 기타 유럽 국가입니다.

독일은 시장 점유율과 수익 면에서 유럽 방광 장애 시장을 지배하고 있으며 예측 기간 동안에도 지배력을 계속 유지할 것입니다. 이는 이 지역에서 과민성 방광 장애가 널리 퍼져 있고, R&D 투자가 증가하고 새로운 치료법이 출시되면서 시장이 활성화되고 있기 때문입니다.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규정의 변화를 제공합니다. 신규 및 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 국내 및 국내 브랜드와의 치열한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.

경쟁 환경 및 유럽 방광 장애 시장 점유율 분석

유럽 ​​방광 장애 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 아시아 태평양 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위의 데이터 포인트는 유럽 방광 장애 시장에 대한 회사의 초점과만 관련이 있습니다.

유럽 ​​방광 장애 시장의 주요 기업으로는 Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (KYORIN Holdings, Inc.의 자회사), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Urovant Sciences 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 유럽 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가에게 전화를 요청하십시오.


SKU-

세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요

  • 대화형 데이터 분석 대시보드
  • 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
  • 사용자 정의 및 질의를 위한 리서치 분석가 액세스
  • 대화형 대시보드를 통한 경쟁자 분석
  • 최신 뉴스, 업데이트 및 추세 분석
  • 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
데모 요청

목차

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE BLADDER DISORDERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 EUROPE BLADDER DISORDERS MARKET, PIPELINE ANALYSIS

5 EUROPE BLADDER DISORDER MARKET: REGULATIONS

5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION

5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS

5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS

6 EUROPE BLADDER DISORDERS MARKET OVERVIEW

6.1 DRIVERS

6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES

6.2 RESTRAINTS

6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT

6.2.2 PRODUCTS RECALLS FROM MARKET

6.3 OPPORTUNITIES

6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

6.3.2 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS

6.4.2 PATENT EXPIRY OF DRUGS

7 EUROPE BLADDER DISORDERS MARKET, BY TYPE

7.1 OVERVIEW

7.2 OVERACTIVE BLADDER

7.3 URINARY INCONTINENCE

7.4 CYSTITIS

7.5 INTERSTITIAL CYSTITIS

7.6 BLADDER CANCER

7.7 OTHERS

8 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 MEDICATION

8.2.1 TOLTERODINE

8.2.2 MIRABEGRON

8.2.3 FESOTERODINE

8.2.4 OXYBUTYNIN

8.2.5 SOLIFENACIN

8.2.6 DARIFENACIN

8.2.7 TROSPIUM

8.2.8 OTHERS

8.3 SURGERY

8.3.1 SURGERY TO INCREASE BLADDER CAPACITY

8.3.2 BLADDER REMOVAL

8.3.3 OTHERS

8.4 OTHERS

9 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT

9.3 RETAIL

10 EUROPE BLADDER DISORDERS MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 CLINICS

10.4 AMBULATORY SURGICAL CENTERS

10.5 OTHERS

11 EUROPE BLADDER DISORDERS MARKET, BY GEOGRAPHY

11.1 EUROPE

11.1.1 GERMANY

11.1.2 U.K.

11.1.3 FRANCE

11.1.4 ITALY

11.1.5 SPAIN

11.1.6 TURKEY

11.1.7 RUSSIA

11.1.8 NETHERLANDS

11.1.9 SWITZERLAND

11.1.10 BELGIUM

11.1.11 REST OF EUROPE

12 EUROPE BLADDER DISORDERS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: EUROPE

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 MERCK AND CO. INC. (2021)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 ASTELLAS PHARMA INC. (2021)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 BOSTON SCIENTIFIC CORPORATION (2021)

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 VIATRIS INC. (2021)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 ABBVIE (2021)

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 AXONICS, INC. (2021)

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 BLUE WIND MEDICAL (2021)

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 COLOPLAST CORP. (2021)

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 LABORIE (2021)

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MEDTRONIC (2021)

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 PFIZER INC. (2021)

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 VALENCIA TECHNOLOGIES (2021)

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 SWATI SPENTOSE (2021)

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 UROVANT SCIENCES (2021)

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 ZYDUS GROUP (2021)

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

표 목록

TABLE 1 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 EUROPE OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 EUROPE BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 9 EUROPE MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 11 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 13 EUROPE OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 15 EUROPE DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 EUROPE HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 EUROPE OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 EUROPE BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 23 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 24 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 25 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 26 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 27 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 GERMANY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 GERMANY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 31 GERMANY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 32 GERMANY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 33 GERMANY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 GERMANY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 U.K. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 U.K. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 37 U.K. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 38 U.K. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 39 U.K. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 U.K. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 FRANCE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 FRANCE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 43 FRANCE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 44 FRANCE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 FRANCE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 FRANCE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 ITALY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 ITALY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 49 ITALY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 50 ITALY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 51 ITALY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 ITALY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 SPAIN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 SPAIN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 55 SPAIN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 56 SPAIN. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 57 SPAIN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 SPAIN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 TURKEY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 60 TURKEY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 61 TURKEY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 62 TURKEY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 63 TURKEY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 64 TURKEY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 65 RUSSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 RUSSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 67 RUSSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 68 RUSSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 69 RUSSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 70 RUSSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 71 NETHERLANDS BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 72 NETHERLANDS BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 73 NETHERLANDS MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 74 NETHERLANDS SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 75 NETHERLANDS BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 76 NETHERLANDS BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 SWITZERLAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 78 SWITZERLAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 79 SWITZERLAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 80 SWITZERLAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 81 SWITZERLAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 82 SWITZERLAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 83 BELGIUM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 BELGIUM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 85 BELGIUM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 86 BELGIUM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 87 BELGIUM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 88 BELGIUM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 89 REST OF EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

그림 목록

FIGURE 1 EUROPE BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 2 EUROPE BLADDER DISORDERS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE BLADDER DISORDERS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE BLADDER DISORDERS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 EUROPE BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE EUROPE BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE BLADDER DISORDERS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE BLADDER DISORDER MARKET

FIGURE 14 EUROPE BLADDER DISORDERS MARKET: BY TYPE, 2021

FIGURE 15 EUROPE BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 EUROPE BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 EUROPE BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021

FIGURE 19 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)

FIGURE 20 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 21 EUROPE BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 23 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 24 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 25 EUROPE BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 26 EUROPE BLADDER DISORDERS MARKET: BY END USER, 2021

FIGURE 27 EUROPE BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 EUROPE BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 EUROPE BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 EUROPE BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 31 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 32 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 EUROPE BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 35 EUROPE BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

자세한 정보 보기 Right Arrow

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.

DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.

사용자 정의 가능

Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.

자주 묻는 질문

The Europe Bladder Disorders Market value is expected USD 5,226.00 million by 2029.
The major countries operating in the Europe Bladder Disorders Market are Germany, France, U.K, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe.
The major players operating in the Europe Bladder Disorders Market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Urovant Sciences among others.
By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) are covered in this report.